Application of Conessine in preparation of medicine for resisting influenza A virus infection
By using natural small molecule compound Conessine to prepare anti-influenza A virus infection drugs, the problem of ineffective treatment of influenza A virus in the prior art has been solved, and efficient and safe viral inhibition effects have been achieved, providing new treatments for global influenza plan.
Patent Information
- Application Number
- CN202411055977.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-02
AI Technical Summary
The prior art lacks effective drugs to inhibit influenza A virus, especially the natural small molecule compound Conessine, which has fewer applications in antiviral aspects, resulting in inefficient global influenza treatment.
The natural Chinese medicine small molecule compound Conessine is used to prepare anti-influenza A virus infection drugs. By inhibiting virus infection and replication, and combining pharmaceutically acceptable carriers, it is prepared into powders, solutions, capsules, granules, tablets, Emulsions, suspensions, etc.
Conessine showed strong anti-influenza A virus inhibitory power, with an IC50 value of 2.07μM, low cytotoxicity, high selection index, and provides a safe and efficient treatment plan, effectively avoiding the side effects of chemical synthetic molecules, and providing global influenza. New effective therapeutic drugs.
Smart Images

Figure CN118948862A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of Conessine in preparing drugs for resisting influenza A virus infection. Background Art
[0002] Influenza A virus (IAV) is a human respiratory pathogen that is widely prevalent around the world. It is highly contagious and pathogenic, and can cause severe respiratory infections, pneumonia, encephalitis and other diseases, and even worse, can lead to death. Influenza A virus belongs to the family of Orthomyxoviridae and is an enveloped negative-strand RNA virus. It can be divided into several subtypes, such as H1N1, H3N2, etc., based on the different antigenic properties of the hemagglutinin protein (HA) and neuraminidase protein (NA) on its surface.
[0003] IAV is also a zoonotic pathogen with multiple hosts. It can be transmitted between species and reclassified into different virus types, which in turn leads to the emergence and widespread spread of new influenza virus epidemics. Among them, the Spanish flu outbreak between 1918 and 1919 was the most serious, causing more than 40 million deaths. Currently, there are few specific drugs for the treatment of influenza A virus, so drugs that have an inhibitory effect on influenza A virus have always been the focus of researchers.
[0004] The method of using natural chemical components extracted from typical Chinese medicine to inhibit IAV has strong medical value and clinical potential, and is in line with the general research direction of combining Chinese and Western medicine. Compared with the artificially synthesized small molecules of medicinal chemistry previously used to inhibit IAV, the natural chemical molecules extracted from plant components can more effectively avoid the possible side effects of chemical synthetic molecules on humans, and are more secure in terms of safety and social promotion.
[0005] Conessine, a natural Chinese medicine small molecule compound, is a steroid alkaloid isolated from Holarrhena floribunda and is one of the important natural active ingredients. Holarrhena floribunda belongs to the genus Holarrhena of the Apocynaceae family. In traditional Chinese medicine, it is mainly used to treat dysentery and flatulence, and has antidiarrheal and antipyretic effects. It has the functions of clearing heat and relieving cough, detoxifying and killing insects, astringing the intestines and relieving diarrhea, cooling blood and stopping dysentery, promoting diuresis and relieving pain. It has a good effect on the treatment of wind-heat colds, liver and gallbladder diseases, gastrointestinal diseases, diarrhea and other diseases.
[0006] In previous studies, the natural Chinese medicine small molecule compound Conessine is generally used as a highly effective and selective H3 receptor antagonist. The current study found that it mainly has anti-malarial activity, anti-dysentery activity, and antibacterial activity such as the inhibitory activity of Pseudomonas aeruginosa efflux pump. At the cellular level, Conessine was found to have the function of regulating autophagy and can inhibit muscle cell death caused by excessive activation of the autophagy pathway induced by hydrogen peroxide. It is already a mature drug small molecule and is derived from natural plant ingredients. Therefore, it has the safety premise of becoming a good inhibitor of influenza A virus.
[0007] However, there are few reports on the antiviral effect of the small molecule compound Conessine. Therefore, further developing the antiviral effect of Conessine is of great significance to solving the global influenza problem. Summary of the invention
[0008] The purpose of the present invention is to provide an application of conessine in the preparation of an anti-influenza A virus infection drug. Conessine is used to treat influenza A virus infection, and the inhibitory effect of the treatment is good and the safety is high.
[0009] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0010] The invention provides application of Conessine in preparing medicine for resisting influenza A virus infection.
[0011] Furthermore, the structure of the Conessine is shown in formula (I):
[0012]
[0013] Furthermore, the Conessine can inhibit the infection and replication of influenza A virus.
[0014] Furthermore, the anti-influenza A virus infection drug may be added with a pharmaceutically acceptable carrier.
[0015] Furthermore, the dosage form of the anti-influenza A virus infection drug is one of powder, solution, capsule, granule, tablet, emulsion and suspension.
[0016] The application of Conessine in the present invention in the preparation of anti-influenza A virus infection drugs has the following beneficial effects compared with the prior art:
[0017] (1) The present invention uses small molecule Conessine to inhibit influenza A virus, and detects the IC50 value of Conessine's inhibitory effect. The results show that Conessine has a strong inhibitory effect on influenza A virus, IC50 = 2.07 μM, which is a low value and has a high inhibitory efficiency. The toxicity of small molecule Conessine to cells was also detected, and it was found that its toxicity to cells was also low, CC50 = 34.11 μM, which is a high value, and the selectivity index (SI) is much higher than the safe range, which is more secure for the safety and effectiveness of Conessine as an IAV influenza A virus inhibitor.
[0018] (2) The present invention uses small molecule Conessine, a natural chemical component extracted from plants, to inhibit influenza A virus, which can effectively avoid the side effects of chemically synthesized molecules and has high safety. In addition, small molecule Conessine has a high inhibition efficiency on influenza A virus. It can be used to treat respiratory infections, pneumonia, encephalitis and other diseases caused by influenza A virus, providing a new effective therapeutic drug for global influenza. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0020] Figure 1 The Conessine cytotoxicity curve and the IAV inhibition rate curve in Experimental Example 1 are shown. DETAILED DESCRIPTION
[0021] The embodiments of the present invention are described in detail below, and the embodiments are intended to explain the present invention and should not be construed as limiting the present invention. If specific techniques or conditions are not specified in the embodiments, they are carried out according to the techniques or conditions described in the literature in this area or according to the product specifications. If the manufacturers of reagents or instruments are not specified, they are all conventional products that can be obtained commercially.
[0022] The small molecule Conessine (alias: Conessinum, Wrightine, Conessin, Roquessine, Neriine, Konessin) used in the following examples of the present invention is produced by targetmo, with product number T20712 CAS 546-06-5.
[0023] The small molecule Conessine of the present invention belongs to steroidal alkaloids, and its molecular formula is: 24 H40 N2, molecular weight: 356.59, structure see formula (I):
[0024]
[0025] Example 1
[0026] Example 1 of the present invention screens drugs for inhibiting influenza A virus, specifically comprising the following steps:
[0027] Preliminary screening of small molecules with IAV inhibitory activity in the drug small molecule library:
[0028] The concentration of drug small molecules in the small molecule library is 10mM (in DMSO). The screened IAV is connected to a gene expressing Gaussia Luciferase (Gluc) luciferase. The infection and replication of the virus in the host cells can be obtained by detecting the value of luciferin after infecting the cells.
[0029] The small molecule Conessine in the small molecule library was diluted 1000 times to 10 μM in Mock DMEM, and then the IAVA / PR / 8 / 34 (PR8)-Gluc strain was added to it. The titer of the original venom was 1.0×10 5 The final venom concentration was diluted 100 times and mixed with MDCK cells for 24 hours before the cells were tested for fluorescence (Gaussia-Lumi TM Conessine was tested by adding positive and negative control groups of pure cells infected with IAV virus and without virus, and the luciferin value of Conessine was close to that of the pure cell control group, while the luciferin values of most other small molecules were close to those of the control group of cells infected with IAV only. It can be seen that Conessine has an inhibition rate of nearly 100% on IAV and can be used to prepare drugs for the treatment of influenza A virus infection.
[0030] Example 2
[0031] In Example 2 of the present invention, Conessine is used to prepare a tablet-type influenza A virus infection-resistant drug, and the specific preparation method is as follows:
[0032] Take Conessine, add conventional excipients for preparing tablets, mix well, and perform tableting.
[0033] Example 3
[0034] In Example 3 of the present invention, a granule of anti-influenza A virus infection drug was prepared using Conessine, and the specific preparation method is as follows:
[0035] Take Conessine, add the conventional auxiliary materials for preparing granules, mix well, and package.
[0036] Example 4
[0037] In Example 4 of the present invention, Conessine is used to prepare an aerosol anti-influenza A virus infection drug, and the specific preparation method is as follows:
[0038] Take Conessine, add conventional excipients for preparing aerosols such as propellants and various additives for filling.
[0039] Example 5
[0040] In Example 5 of the present invention, a capsule-based drug for preventing influenza A virus infection is prepared using Conessine. The specific preparation method is as follows:
[0041] Take Conessine, add conventional excipients for preparing capsules and mix well, quantitatively fill into a capsule shell made of gelatin as the main material and seal it.
[0042] Test Example 1
[0043] Test Example 1 of the present invention detected the inhibitory effect of Conessine on IAV and its cytotoxicity, and the specific method was as follows:
[0044] (1) Inhibition effect detection:
[0045] The small molecule Conessine was diluted in Mock DMEM to concentrations of 50 μM, 25 μM, 10 μM, 5 μM, 2.5 μM, 1 μM, 0.1 μM, and 0.01 μM. Different concentrations of Conessine were used to treat MDCK cells. At the same time, the MDCK cells were infected with IAV-Gluc. Luciferase detection was performed and the value was read 24 hours after infection. The curve analysis of the results was then performed to finally obtain the small molecule concentration value IC that achieved half the inhibition rate. 50 , the results are shown in Figure 1 .
[0046] (2) Cytotoxicity assay:
[0047] The small molecule Conessine was diluted in Mock DMEM to a concentration of 1000 μM, 100 μM, 50 μM, 25 μM, 10 μM, 5 μM, 2.5 μM, 1 μM, 0.33 μM, 0.1 μM, and 0.01 μM. The cells were incubated with small molecule Conessine at different concentrations, and five groups of cells under the same conditions were set up for average control. The cytotoxicity was measured by the CCK8 kit (Enhanced Cell Counting Kit-8 Bio-Tech), and the cytotoxicity curve of the small molecule was drawn. The curve analysis of the results was then performed to finally obtain the small molecule concentration value CC at which the cytotoxicity reached half. 50 , the results are as follows Figure 1 shown.
[0048] Depend on Figure 1 It can be seen that Conessine has a strong inhibitory effect on influenza A virus, IC 50= 2.07μM, a lower value. CC 50 =34.11 μM, which is a relatively high value, has a lower toxicity to cells, and the selectivity index (SI) is much higher than the safe range, which provides better assurance for the safety and effectiveness of Conessine as an IAV influenza A virus inhibitor.
[0049] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of Conessine in the preparation of drugs against influenza A virus infection.
2. The use of Conessine according to claim 1 in preparing drugs for preventing influenza A virus infection, characterized in that: The structure of the Conessine is shown in formula (I):
3. The use of Conessine according to claim 2 in preparing drugs for preventing influenza A virus infection, characterized in that: The conessine can inhibit the infection and replication of influenza A virus.
4. The use of Conessine according to claim 3 in preparing a drug for preventing influenza A virus infection, characterized in that: The anti-influenza A virus infection drug may be added with a pharmaceutically acceptable carrier.
5. The use of Conessine according to claim 4 in preparing a drug for resisting influenza A virus infection, characterized in that: The dosage form of the anti-influenza A virus infection drug is one of powder, solution, capsule, granule, tablet, emulsion and suspension.
Citation Information
Patent Citations
Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof
CA2717119A1
Application of coneine in preparation of anti-herpes virus medicine
CN117205221A
Use of hydroxyzine and antihistamine analogs for treating the covid-19 disease
EP3973961A1
Composition for preventing or treating of autophagy mediated disease comprising conessine as an active ingredient
KR101770395B1
Inhibitors of zika virus infection
WO2021035068A2
